tbuckley/cabot-search huggingface dataset:
Hypervariable region sequence in cryoglobulin-associated hepatitis C virus in sera of patients with chronic hepatitis C: Relationship to antibody response against hypervariable region genom
Authors: T Aiyama
Journal: Hepatology (1996)

Essential mixed cryoglobulinemia is frequently associated with hepatitis C virus (HCV) infection, with the formation of HCV antigen/antibody complexes. The hypervariable region (HVR) of the HCV E2/NS1 region is thought to include epitopes for neutralizing antibodies, but it remains uncertain whether cryoglobulins (CGs) contain such antibody-bound HCV. Thus, we studied HVR clones isolated from cryoprecipitate and supernatant in the sera of four chronic hepatitis C patients with cryoglobulinemia, and expressed as fusion proteins with glutathione S-transferase (GST). Patients' sera were tested for antibody binding to the proteins. The rate of anti-HVR antibody-positive clones was significantly higher in cryoprecipitate (89% ± 13%, P < .05) than in supernatant (41% ± 25%). Both HCV RNA and anti-HVR antibody were more concentrated in cryoprecipitates compared with those of serum and supernatant in two patients tested. Anti-HVR antibody-positive clones in cryoprecipitate showed common amino acid (aa) sequences in each of the four patients. Similarly, all the antibody-positive clones in supernatant showed the same aa sequences for three of the four patients. When aa sequences were compared with those of reported isolates with genotype 1b, the mean percentage of aa difference was greater in the clones from supernatant and in anti-HVR antibody-negative clones than in the clones from cryoprecipitate and in the antibody-positive clones, respectively. These findings indicate that serum CG contains anti-HVR antibody-bound HCV in patients with chronic hepatitis C. Anti-HVR antibody-free individual clones, which were more frequently noted in supernatant, showed closely related sequences, but which were of a heterogeneous quasispecies nature.
<i>Lectures on Some Points in the Treatment and Management of Neuroses.</i>By E. C Seguin, M. D.. Providence, R. I., Corresponding Member of the Société De Biologic of Paris, and of the Verein Für Medicin of Berlin, etc. Reprinted from<i>The New York Medical Journal</i>for April 5, 26, May 17, 31, 1890
Authors: H. S. W.
Journal: American Journal of Psychiatry (1891)
The Therapeutic Uses of Narcotic Drugs.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SIR WILLIAM GULL
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Data Processing and Patient Eligibility Indicator Errors in Study About Dose Tapering Among Patients Prescribed Long-term Opioid Therapy
Journal: JAMA Network Open (2020)

Joshua J. Fenton, MD, MPH; Alicia L. Agnoli, MD, MPH, MHS; Guibo Xing, PhD; Lillian Hang, MBA, MPH; Aylin E. Altan, PhD; Daniel J. Tancredi, PhD; Anthony Jerant, MD; Elizabeth Magnan, MD, PhD
Ehrlichia
Authors: J. Stephen Dumler
Journal: JAMA (1991)

<h3>To the Editor.</h3> — During the recent sesquiannual meeting of the American Society for Rickettsiology and Rickettsial Diseases held in Galveston, Tex, several investigators presented data concerning human ehrlichiosis, a newly recognized human zoonosis. Also published in the April 24 issue of<i>JAMA</i>was a report<sup>1</sup>that was misleading and implied the discovery of the agent of human ehrlichiosis by me and my coworkers. In fact, the report concerns data we presented at the March 1991 annual meeting of the United States and Canadian Academy of Pathology, which details the pathology of several cases and the first documentation of an immunohistologically identified<i>Ehrlichia</i>in human tissues from one case of fatal ehrlichiosis. During the meeting of rickettsiologists, Jacqueline Dawson, MS, of the Centers for Disease Control, Atlanta, Ga, described the first isolation of<i>Ehrlichia</i>organisms from a patient in the United States.<sup>2</sup>Ms Dawson and her Centers for
Failure of recommended treatment for secondary syphilis
Authors: N. J. Fiumara
Journal: JAMA (1986)

<h3>To the Editor.—</h3> In the April 4 issue of<i>JAMA</i>, Conant et al<sup>1</sup>indicate that commercial condoms, including those derived from sheep intestinal membranes (natural condoms), are effective in preventing the in vitro transmission of retrovirus infection.<sup>1</sup>Their conclusion is based on experiments in which condoms containing a solution of either mouse retrovirus or acquired immunodeficiency syndrome-associated retrovirus were fit over the plunger of a 12-mL plastic syringe, reinserted inside syringe barrels, and submerged in a beaker containing sterile culture media. After repeated aspirations and expulsions the authors found the beaker culture media to be free of retrovirus. In a somewhat similar series of experiments addressing the issue of hepatitis B virus infection, we reported that, while synthetic condoms do indeed prevent leakage of iodine 125-labeled hepatitis B surface antigen (HBsAg), natural condoms do not.<sup>2</sup> There are a number of possible explanations for the apparent discrepancy between
Successful detoxification from methadone maintenance. Follow-up study of 38 patients
Authors: C. E. Riordan
Journal: JAMA (1976)

Thirty-eight patients were successfully detoxified from maintenance with methadone hydrochloride. Contrary to results of most previous studies, a substantial number of individuals were found to have remained drug-free, employed, and uninvolved with the criminal justice system since detoxification. Almost half of those who returned to drug use have become reinvolved in treatment. Escalated alcohol use occurred during and following methadone maintenance. (<i>JAMA</i>235:2604-2607, 1976)
DIET AND HEALTH.
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathobiology Annual. 1982. Volume 12.
Journal: Annals of Internal Medicine (1983)

Counterelectrophoresis on Human Serum in Coxsackie Virus InfectionsEncouraging results have been obtained by Schmidt et al (1968;1973) on the diagnosis of Coxsackie infections using gel diffusion for demonstration of anti- body in patients' sera.They found that with concentrated Coxsackie antigens human serum pro- duced a group line close to the antigen cup with antigens not necessarily of the infecting virus type, and a specific line, closer to the serum cup, consisting of IgM antibody combined with intact virus particles, of the current infecting virus type, or occasionally with virus for which the serum had a high neutralizing anti- body level.When antigen was inactivated by heat- ing at 56°C for 30 min the specific antigen was converted to group antigen.Counterelectrophoresis should theo- retically enable a less concentrated antigen to be used and be more rapid than simple gel diffusion, but preliminary studies have proved disappointing.Counterelectrophoresis and antigen preparation were as described (Mac-William and Cook, 1975).Antigens
Medical News
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy
Authors: G. L. Vega
Journal: JAMA (1990)

A common pattern of dyslipidemia is elevated levels of plasma triglyceride, borderline high total cholesterol, reduced high-density lipoprotein, and increased apolipoprotein B. This pattern of dyslipidemia frequently is associated with premature coronary heart disease. Nicotinic acid is the drug of first choice for this pattern. In this study, gemfibrozil and lovastatin were compared for their effects on the overall lipoprotein profile in 13 men with this type of dyslipidemia. Both drugs significantly reduced very-low—density lipoprotein and intermediate-density lipoprotein cholesterol levels, and both modestly raised high-density lipoprotein cholesterol levels. Gemfibrozil therapy, however, failed to reduce total cholesterol or total apolipoprotein B levels, whereas lovastatin therapy lowered levels of total cholesterol by 28%, low-density lipoprotein cholesterol by 33%, and total apolipoprotein B by 32%. Moreover, lovastatin therapy caused greater declines in lipoprotein cholesterol ratios than gemfibrozil therapy. Lovastatin thus seems to have certain advantages over gemfibrozil for treatment of elevated plasma triglyceride levels accompanied by borderline high total cholesterol and raised apolipoprotein B levels; therefore, lovastatin therapy should be considered as one approach for management of this condition. (<i>JAMA</i>. 1990;264:2759-2763)
Journal of Bacteriology, Baltimore
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality of Care
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trephine drill biopsy of the lung. Cleveland clinic experience
Authors: G. Castillo
Journal: JAMA (1974)

One hundred thirteen biopsies were performed with use of a high-speed drill in 100 patients with diffuse lung disease. Adequate lung tissue was obtained in 70% of the biopsies. Pneumothorax resulted in 40% of the biopsies, but intubation treatment was required in only 7%. Hemoptysis occurred in 8%, pleuritic chest pain in 17%, and subcutaneous emphysema in 4%. Most of the biopsies in our patients were office procedures, since our offices are a part of the hospital complex, but when the patient has advanced pulmonary function impairment, hospitalization is preferred for the trephine biopsy procedure. Trephine lung biopsy is a simple, useful, and relatively inexpensive procedure. Serious complications are infrequent. (<i>JAMA</i>228:189-191, 1974)
Abnormal Pap smears, ASCUS still ob/gyn puzzle
Authors: K. Titus
Journal: JAMA (1996)

WHEN IT comes to the management of women with abnormal Papanicolau (Pap) smears, clinicians are likely to respond to questions about ASCUS—atypical squamous cells of undetermined significance—with a simple but telling phrase: "Don't ask us." While the term 'ASCUS' is used to define Pap smears containing squamous cells of abnormal appearance that do not meet the criteria for defined epithelial abnormalities, on a practical level the diagnosis represents an "I-don't-know" category, noted Ralph M. Richart, MD, in a presentation at the annual meeting of the American College of Obstetricians and Gynecologists. Consequently, an ASCUS diagnosis presents vexing problems for cytopathologists, obstetricians, and gynecologists. The ASCUS category is filled with a variety of patients: those with low-grade squamous intraepithelial lesions (LSIL), high-grade squamous epithelial lesions, and hidden invasive cancers. "ASCUS has become kind of a wastebasket, like Class 2 smears were years ago," says Raymond H. Kaufman, MD, a professor in
Cost of Respiratory Effort in Postoperative Cardiac Patients N. Thung, P. Herzog, I. I. Christlieb, W. M. Thompson, Jr., and J. F. Dammann, Jr.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3249: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells
Authors: Julie Preillon, Sofie Denies, Diane Jamart, Matthew J. Carter, Mark S. Cragg, Gregory Driessens
Journal: Cancer Research (2019)

Abstract T cell Immunoreceptor with Ig and ITIM domains (TIGIT) is a co-inhibitory receptor expressed by lymphocytes, preferentially CD8+ T cells, NK, as well as regulatory T cells (Treg). TIGIT can be bound by several ligands including CD155 and CD112 that are frequently expressed by tumor cells. In cancer, TIGIT expression is upregulated on conventional T cells and even more on regulatory T cells. Co-expression with exhaustion markers such as PD-1 is common, giving a strong rationale for blocking TIGIT as a therapeutic approach for reversing T or NK cell dysfunction linked with cancer progression. The mechanism of action of novel a-TIGIT monoclonal antibody (mAb) was characterized in vivo in the murine CT26 tumor model. This model mimics the human situation based on expression of TIGIT ligands on tumor cells and infiltration by effector and regulatory T cells that express higher levels of TIGIT compared to splenocytes. Two different isotypes (mIgG2a and mIgG1) of a-TIGIT mAb were used to evaluate anti-tumor efficacy, with only the mIgG2a, deleting isotype able to induce strong antitumor efficacy. The importance of Fc gamma receptors (FcγR) for the antitumor efficacy of a-TIGIT activity was further demonstrated by the use of mice KO for activatory FcγR or by depletion of NK cells which also resulted in the loss of a-TIGIT activity. The anti-tumor efficacy of a-TIGIT mAb was associated with an increased activity of conventional CD8+ and CD4+ T cells but also with a preferential depletion of Treg within the tumor microenvironment. This activity also correlated with full occupancy of TIGIT receptor in mice. As it has been shown that TIGIT is expressed on tumor cells in certain hematological cancers, we also established a model of EL4 tumor with engineered TIGIT expression. In this model, a-TIGIT demonstrates a strong antitumor effect that strictly depends on the isotype of the mAb. Finally, the activity of a-TIGIT was tested in less immunogenic models including of pancreatic PancO2 cancer where it demonstrated some tumor growth delay as a single agent and very strong combination potential with other immune checkpoints. In summary, these results show that antitumor mediated efficacy of a-TIGIT mAb depends upon target binding and also on interaction with FcγR. These findings support the clinical evaluation of a-TIGIT mAb able to engage those receptors. Citation Format: Julie Preillon, Sofie Denies, Diane Jamart, Matthew J. Carter, Mark S. Cragg, Gregory Driessens. a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3249.
Emotional Deprivation and Growth Retardation Simulating Idiopathic Hypopituitarism
Authors: G. F. Powell, J. A. Brasel, R. M. Blizzard
Journal: New England Journal of Medicine (1967)

DURING the past six years we have observed and evaluated 13 children, most of whom initially were believed to have growth failure on the basis of idiopathic hypopituitarism. However, a number of unusual features were noted in the histories that suggested emotional disturbances in the children and abnormal home environments. These were not common to the histories of patients with idiopathic hypopituitarism. When these patients were placed in a convalescent hospital, they demonstrated remarkable growth acceleration without receiving growth hormone or other agents. Detailed studies were performed before and during the period of rapid growth. This paper presents the clinical . . .